U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07726693) titled 'Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial' on July 07.
Brief Summary: Liver disease is the only common cause of death that is increasing in numbers. Once people develop severe scarring (cirrhosis), there are no medications proven to help them live longer, healthier lives. Apixaban is already commonly used to prevent or treat blood clots and is known to be safe for those with cirrhosis.
In the early stages of cirrhosis, most people have no symptoms and lead normal lives; this is called "compensated" cirrhosis. However, when the liver stops working properly, they develop "decompensated" cirrhosis, which causes...